Category: Corporate NewsBy Rameda Admin30 سبتمبر، 2024 Author: Rameda Admin Post navigationPreviousPrevious post:Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketNextNext post:Earning Release One Pager 3Q24Related Postsأول صفقات راميدا في 2025 إضافة استراتيجية لمحفظة أدوية الأمراض المزمنة7 يوليو، 2025إفصاح توزيع أرباح قياسية7 يوليو، 2025Rameda One-Pager 1Q2513 مايو، 2025Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical Market9 سبتمبر، 2024Rameda Announces Price Increase Approvals for All Its Top Products7 أغسطس، 2024Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose Intolerance28 مايو، 2024
Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical Market9 سبتمبر، 2024
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose Intolerance28 مايو، 2024
